Product Program year 2025 Source: CMS Open Payments

Licart

Drug non-opioid analgesic

NDC 71858-0305-5

Open in the dashboard

General payments

$848,437

39,572 payments

Research payments

$301,518

53 payments

Through program year 2025, $848,437 in general payments and $301,518 in research payments were reported against Licart (non-opioid analgesic).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Amount Payments
2025 General $133,519 6,763
2025 Research $176,651 33
2024 General $181,050 8,076
2024 Research $9,853 4
2023 General $240,931 11,150
2023 Research $83,838 14
2022 General $177,854 8,469
2021 General $102,825 4,705
2021 Research $18,825 1
2020 General $12,258 409
2020 Research $12,350 1

Breakdown

Who paid General payments · program years 2020–2025
  1. IBSA Pharma Inc. $842,737 39,569 payments
  2. IBSA Institut Biochimique SA $5,700 3 payments
Top recipients General payments · program year 2025
  1. Susan Rose Pediatric Endocrinology · Cincinnati, OH $1,963 1% · 1 payment
  2. Philip Doh Pain Medicine · Los Angeles, CA $501 <1% · 38 payments
  3. Sherry Sussman Endocrinology, Diabetes & Metabolism · Smithtown, NY $403 <1% · 4 payments
  4. Nick Lee Internal Medicine · Los Angeles, CA $336 <1% · 22 payments
  5. Singh Boun Family Medicine · Monterey Park, CA $290 <1% · 20 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Endocrinology, Diabetes & Metabolism Internal Medicine $26,348 20% · 663 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $19,706 15% · 689 practitioners
  3. Family Medicine $17,070 13% · 641 practitioners
  4. Internal Medicine $14,132 11% · 501 practitioners
  5. Physician Assistant $13,455 10% · 421 practitioners

The top 5 of 93 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $17,055 13% · 383 recipients
  2. Texas $15,854 12% · 565 recipients
  3. Florida $15,667 12% · 460 recipients
  4. New York $11,686 9% · 386 recipients
  5. New Jersey $7,367 6% · 297 recipients

The top 5 of 49 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

6,993

Prescriptions dispensed, refills included

Drug cost

$6,086,786

Paid at the pharmacy, in all

Prescribers

142

With 11 or more claims of it

Medicare Part D drugs matched to Licart, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Licart Diclofenac Epolamine Same name 142 6,993 $6,086,786

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Sonia Walker-Adamson Family Practice NY 1,273 $915,073 None on record
Jiho Choi Family Practice VA 425 $312,011 $169
Philip Doh Interventional Pain Management CA 384 $579,839 $1,530
Shawn Kim Internal Medicine GA 333 $273,984 $28
Dustin Nguyen Internal Medicine NY 310 $283,061 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
39,572 general · 53 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record